This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in this journal  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Several articles in the May 27 issue of the ARCHIVES helped to clarify some of the clinical issues regarding the risk of cardiovascular events in patients treated with COX-2 inhibitors. The editorial by Dalen¹ noted that many users of NSAIDs and COX-2 inhibitors are in the age group that has or is at risk of having coronary artery disease and suggested that "the concomitant use of low-dose aspirin (80 mg/d) should be strongly considered in patients with a history of coronary artery disease, stroke, transient ischemic attack, or peripheral vascular disease." In our respectful opinion, the concomitant use of aspirin and COX-2 inhibitors may not represent the most cost-effective approach to patient treatment. The addition of aspirin to a COX-2 inhibitor regimen changes the balance of incremental costs and benefits of COX-2 inhibitors over standard NSAID therapy.

When COX-2 inhibitors were introduced to the marketplace, the justification for a premium . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Naproxen's Interaction With Aspirin May Affect Its Cardioprotective Effect
Stephen Schechter
Arch Intern Med. 2003;163(11):1374.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

NSAIDs: the Emperor's new dogma?
Bjarnason et al.
Gut 2003;52:1376-1378.
ABSTRACT | FULL TEXT  

COX-2 inhibitors and type 4 error
Pijak and Gazdik
CMAJ 2003;169:190-190.
FULL TEXT